

Table S1 . Treatment of patients

A) Baseline patients

Diagnostic Group	Treatment	Frequency	Percent
LHD-PH NO CTD	Calcium channel blocker	1	1.0
	None	96	93.2
	oral monotherapy	6	5.8
	Total	103	100.0
LUNG-PH NO CTD	Calcium channel blocker	1	0.7
	None	85	57.8
	oral dual therapy	6	4.1
	oral monotherapy	48	32.7
	prostenoid mono	2	1.4
	prostenoid oral	4	2.7
	Unknown	1	0.7
Total	147	100.0	
CTEPH	Pulmonary endarterectomy	94	46.5
	Calcium channel blocker	1	0.5
	None	90	44.6
	oral dual therapy	11	5.4
	oral monotherapy	87	43.1
	prostenoid mono	7	3.5
	prostenoid oral	2	1.0
	Unknown	4	2.0
Total	202	100.0	
UNCLEAR	None	10	37.0
	oral dual therapy	2	7.4
	oral monotherapy	10	37.0
	prostenoid mono	5	18.5
	Total	27	100.0

B) Patients at 1 year follow-up (n=150)

Diagnostic Group	Treatment	Frequency	Percent
LHD-PH	None	8	61.5
	oral monotherapy	5	38.5
LUNG-PH	None	9	26.5
	oral dual therapy	2	5.9
	oral monotherapy	21	61.8
	prostenoid mono	1	2.9
	prostenoid oral	1	2.9
All CTEPH	Pulmonary endarterectomy	49	52.6
	Calcium channel blocker	1	1.1
	None	42	45.2
	oral dual therapy	6	6.5
	oral monotherapy	36	38.7
	prostenoid mono	4	4.3
	prost oral	1	1.1
	Unknown	3	3.2
CTEPH – had surgery	NONE	32	65.3
	oral monotherapy	11	22.4
	oral dual therapy	1	2.0
	prostenoid mono	2	4.1
	prostenoid oral	1	2.0
Unclear	none	2	20.0
	oral dual therapy	1	10.0
	oral monotherapy	5	50.0
	prostenoid mono	2	20.0

LHD: left heart disease; PH: pulmonary hypertension; CTEPH: chronic thromboembolic pulmonary hypertension

		N	201	200	192	200	197	200	201	146
	Levels 5	r	-.314**	-.141*	-.273**	.303**	.302**	.408**	-.541**	-.375**
	%pred	p	.000	.047	.000	.000	.000	.000	.000	.000
		N	201	200	192	200	197	200	201	146
Group 5	ISWD m	r	.036	-.052	-.153	.488**	.425*	.236	-.640**	-.571*
		p	.858	.797	.445	.010	.031	.236	.000	.013
		N	27	27	27	27	26	27	27	18
	ISWD %pred	r	-.052	-.183	-.216	.531**	.500**	.263	-.697**	-.521*
		p	.798	.360	.280	.004	.009	.184	.000	.026
		N	27	27	27	27	26	27	27	18
	Levels 5 Distance	r	.000	.021	-.033	.349	.308	.128	-.552**	-.555*
		p	.998	.917	.870	.074	.126	.523	.003	.017
		N	27	27	27	27	26	27	27	18
	Levels 5 %pred	r	.061	-.117	-.152	.408*	.351	.150	-.569**	-.601**
		p	.764	.561	.450	.035	.079	.455	.002	.008
		N	27	27	27	27	26	27	27	18
Age >65	ISWD m	r	-.206**	-.283**	-.293**	.300**	.276**	.228**	.333**	-.534**
		p	.001	.000	.000	.000	.000	.000	.000	.000
		N	272	272	266	270	269	268	246	272
	ISWD %pred	r	-.188**	-.338**	-.319**	.266**	.272**	.235**	.392**	-.568**
		p	.002	.000	.000	.000	.000	.000	.000	.000
		N	272	272	266	270	269	268	246	272
	Levels 5 Distance	r	-.232**	-.282**	-.296**	.307**	.279**	.218**	.334**	-.542**
		p	.000	.000	.000	.000	.000	.000	.000	.000
		N	272	272	266	270	269	268	246	272
	Levels 5 %pred	r	-.217**	-.344**	-.335**	.291**	.282**	.244**	.370**	-.558**
		p	.000	.000	.000	.000	.000	.000	.000	.000
		N	272	272	266	270	269	268	246	272

** . Correlation is significant at the 0.01 level (2-tailed).

* . Correlation is significant at the 0.05 level (2-tailed).

ISWD: Incremental Shuttle Walk Test distance; mRAP: mean right atrial pressure; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; CO: cardiac output; CI: cardiac index; SmvO₂: mixed venous oxygen saturation; WHO: World Health Organization